Form 4: HealthEquity Executive Sells Shares Under Pre-Arranged Trading Plan

A HealthEquity executive sold shares under a pre-arranged trading plan, with transactions occurring on December 9, 2024.

Summary

• Robert W. Selander, a HealthEquity executive, executed multiple transactions involving the company's common stock on December 9, 2024.
• These transactions included both the acquisition and sale of shares, as well as the granting of stock options.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on July 9, 2024.
• A total of 5,750 shares were sold at a weighted average price of $101.5553, with individual sales ranging from $101.01 to $101.95.
• An additional 2,500 shares were sold at a weighted average price of $101.5666, with individual sales ranging from $101.145 to $101.950.
• The executive also acquired 12,500 shares at $28.68 and 7,500 shares at $21.27.
• Stock options to purchase 12,500 shares at $0 and 7,500 shares at $0 were also granted, exercisable immediately.

Sentiment

Score: 5

Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, which is neither particularly positive nor negative. The sales are balanced by the acquisition of shares and option grants.

Positives

• The executive's acquisition of shares at lower prices could indicate a belief in the company's long-term value.
• The granting of stock options could incentivize the executive to improve company performance.

Negatives

• The sale of 8,250 shares by the executive could be perceived negatively by some investors, although it was part of a pre-arranged plan.
• The sales occurred at a price range of $101.01 to $101.95, which may indicate a lack of confidence in further price appreciation.

Risks

• Executive stock sales, even under pre-arranged plans, can sometimes create uncertainty in the market.
• The market may interpret the sales as a lack of confidence in the company's future performance.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on July 09, 2024.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and the use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of insider trading. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including competitors such as WageWorks (now HealthEquity) and Benefitfocus.
• The price range of the sales is within the typical range for executive stock sales, which often occur at market prices.
• The option grants are also standard practice for executive compensation, similar to those seen at other companies in the healthcare technology sector.

Stakeholder Impact

• Shareholders may be interested in the executive's trading activity, but the pre-arranged nature of the sales mitigates potential concerns.
• The stock option grants could incentivize the executive to improve company performance, which would benefit shareholders.

Key Dates

Keywords

HealthEquity, executive, stock sales, Rule 10b5-1, trading plan, stock options, insider trading, common stock